UBS Group’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $26.2M | Buy |
1,428,843
+1,121,709
| +365% | +$18.1M | ﹤0.01% | 2410 |
|
|
2026
Q1 | $6.01M | Buy |
307,134
+142,314
| +86% | +$4.23M | ﹤0.01% | 3868 |
|
|
2025
Q4 | $5.13M | Sell |
164,820
-282,857
| -63% | -$7.76M | ﹤0.01% | 4004 |
|
|
2025
Q3 | $9.66M | Sell |
447,677
-85,966
| -16% | -$1.55M | ﹤0.01% | 3325 |
|
|
2025
Q2 | $7.46M | Buy |
533,643
+29,458
| +6% | +$400K | ﹤0.01% | 3432 |
|
|
2025
Q1 | $6.8M | Sell |
504,185
-7,886
| -2% | -$134K | ﹤0.01% | 3468 |
|
|
2024
Q4 | $9.82M | Buy |
512,071
+427,338
| +504% | +$9.29M | ﹤0.01% | 3068 |
|
|
2024
Q3 | $1.93M | Sell |
84,733
-145,643
| -63% | -$2.38M | ﹤0.01% | 4029 |
|
|
2024
Q2 | $3M | Sell |
230,376
-149,208
| -39% | -$2.07M | ﹤0.01% | 3349 |
|
|
2024
Q1 | $6.65M | Buy |
379,584
+236,198
| +165% | +$4.58M | ﹤0.01% | 2659 |
|
|
2023
Q4 | $3.12M | Buy |
143,386
+74,970
| +110% | +$1.18M | ﹤0.01% | 3316 |
|
|
2023
Q3 | $1.05M | Sell |
68,416
-11,165
| -14% | -$213K | ﹤0.01% | 4030 |
|
|
2023
Q2 | $1.89M | Buy |
79,581
+10,790
| +16% | +$277K | ﹤0.01% | 3579 |
|
|
2023
Q1 | $1.75M | Sell |
68,791
-76,987
| -53% | -$2.47M | ﹤0.01% | 3570 |
|
|
2022
Q4 | $4.26M | Buy |
145,778
+96,481
| +196% | +$2.22M | ﹤0.01% | 2663 |
|
|
2022
Q3 | $1.01M | Buy |
49,297
+49,284
| +379,108% | +$886K | ﹤0.01% | 3747 |
|
|
2022
Q2 | $0 | Sell |
13
-209
| -94% | -$2.81K | ﹤0.01% | 10996 |
|
|
2022
Q1 | $4K | Buy |
222
+209
| +1,608% | +$4.02K | ﹤0.01% | 9327 |
|
|
2021
Q4 | $0 | Sell |
13
-1,430
| -99% | -$26.6K | ﹤0.01% | 10748 |
|
|
2021
Q3 | $24K | Buy |
1,443
+1,430
| +11,000% | +$21K | ﹤0.01% | 6984 |
|
|
2021
Q2 | $0 | Hold |
13
| – | – | ﹤0.01% | 9857 |
|
|
2021
Q1 | $0 | Sell |
13
-2,229
| -99% | -$41.7K | ﹤0.01% | 9525 |
|
|
2020
Q4 | $36K | Buy |
2,242
+2,229
| +17,146% | +$33.6K | ﹤0.01% | 6487 |
|
|
2020
Q3 | $0 | Sell |
13
-795
| -98% | -$11.9K | ﹤0.01% | 8437 |
|
|
2020
Q2 | $13K | Sell |
808
-492
| -38% | -$5.59K | ﹤0.01% | 6851 |
|
|
2020
Q1 | $9K | Buy |
1,300
+1,287
| +9,900% | +$15K | ﹤0.01% | 7021 |
|
|
2019
Q4 | $0 | Hold |
13
| – | – | ﹤0.01% | 8441 |
|
|
2019
Q3 | $0 | Sell |
13
-5
| -28% | -$111 | ﹤0.01% | 8280 |
|
|
2019
Q2 | $0 | Buy |
18
+5
| +38% | +$201 | ﹤0.01% | 8190 |
|
|
2019
Q1 | $1K | Sell |
13
-730
| -98% | -$33K | ﹤0.01% | 7565 |
|
|
2018
Q4 | $34K | Buy |
743
+31
| +4% | +$1.79K | ﹤0.01% | 6393 |
|
|
2018
Q3 | $60K | Buy |
712
+411
| +137% | +$38.8K | ﹤0.01% | 6029 |
|
|
2018
Q2 | $29K | Buy |
301
+127
| +73% | +$13.4K | ﹤0.01% | 6418 |
|
|
2018
Q1 | $18K | Buy |
174
+10
| +6% | +$1.09K | ﹤0.01% | 6477 |
|
|
2017
Q4 | $26K | Buy |
164
+135
| +466% | +$17.2K | ﹤0.01% | 6360 |
|
|
2017
Q3 | $4K | Sell |
29
-76
| -72% | -$12.8K | ﹤0.01% | 7324 |
|
|
2017
Q2 | $20K | Buy |
+105
| New | +$17.7K | ﹤0.01% | 6306 |
|
|
2016
Q4 | – | Sell |
-9
| Closed | -$1K | – | 8066 |
|
|
2016
Q3 | $1K | Buy |
+9
| New | +$1K | ﹤0.01% | 7549 |
|
|
2016
Q2 | – | Sell |
-79
| Closed | -$9K | – | 7999 |
|
|
2016
Q1 | $9K | Sell |
79
-11
| -12% | -$1.41K | ﹤0.01% | 6730 |
|
|
2015
Q4 | $15K | Buy |
90
+62
| +221% | +$11.9K | ﹤0.01% | 7017 |
|
|
2015
Q3 | $6K | Buy |
+28
| New | +$9.83K | ﹤0.01% | 7622 |
|
|
2015
Q2 | – | Sell |
-17
| Closed | -$8K | – | 8872 |
|
|
2015
Q1 | $8K | Buy |
17
+5
| +42% | +$2.89K | ﹤0.01% | 7834 |
|
|
2014
Q4 | $7K | Buy |
+12
| New | +$8.63K | ﹤0.01% | 8729 |
|
Other funds holding VRDN
BG
PBA
KCM
FFM
DTC
UBS Group's VRDN Position: Q2 2026 in Review
UBS Group increased its Viridian Therapeutics (VRDN) stake by 365% in Q2 2026, buying an estimated $18.1M and bringing the position to 1,428,843 shares worth $26.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2410.
UBS Group first reported a position in VRDN in Q4 2014 and has held it in 43 quarters since. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.
- UBS Group held 1,428,843 shares of Viridian Therapeutics worth $26.2M as of Q2 2026.
- UBS Group bought 1,121,709 Viridian Therapeutics shares in Q2 2026, an estimated $18.1M.
- Viridian Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2410 holding.
- UBS Group first reported a position in Viridian Therapeutics in Q4 2014 and has held it in 43 quarters since.
- 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.